ClinConnect ClinConnect Logo
Search / Trial NCT03637062

Verify the Safety and Effectiveness of the Cerclage Pessary in Prevention and Treatment of High-risk Preterm Pregnancy

Launched by QH MEDICAL TECHNOLOGY LTD. · Aug 15, 2018

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at a device called a cerclage pessary, which is designed to help prevent and treat preterm labor in women who are at high risk for having their babies too early. The study aims to see if this device is safe and effective for women who have previously had a preterm birth before 34 weeks of pregnancy or have experienced late miscarriage. Women between 18 and 40 weeks of pregnancy who meet these criteria may be eligible to participate.

If you join this study, you’ll receive the cerclage pessary, and doctors will monitor your pregnancy closely to see how well it works for you. Before joining, there are some important health factors to consider, such as not having certain medical conditions or complications that could affect the use of the pessary. This study is not yet recruiting participants, but it’s an important step towards helping women at risk of preterm labor have healthier pregnancies.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Women with a pregnancy and a history of at least one spontaneous preterm birth before 34+0 weeks and/or a history of late abortion
  • 12+0 -18+0 weeks of gestation
  • Minimal age of 18 years
  • Informed consent signature
  • Exclusion Criteria:
  • The previous preterm delivery is iatrogenic proterm labor
  • Major fetal abnormalities (requiring surgery or leading to infant death or severe handicap)
  • The pregnant woman with severe cervical erosion, cervical polyp, hemorrhage and the doctors think she could not use cerclage pessary
  • The pregnant woman with uterine cervicitis
  • The pregnant woman that has been confirmed premature birth
  • Cerclage prior to randomisation
  • Cerclage prior to randomisation
  • Placenta previa totalis
  • Active vaginal bleeding at the moment of randomization
  • Spontaneous rupture of membranes at the time of randomization
  • Silicone allergy
  • Painful regular uterine contractions
  • The pregnant woman have the indication of operation cervical cerclage
  • Current participation in other RCT

About Qh Medical Technology Ltd.

qh medical technology ltd. is a leading innovator in the medical technology sector, dedicated to advancing healthcare through the development of cutting-edge solutions. With a strong focus on research and development, the company specializes in creating innovative devices and technologies that enhance patient outcomes and streamline clinical processes. Committed to rigorous clinical trials and regulatory compliance, qh medical technology ltd. collaborates with healthcare professionals and institutions to ensure its products meet the highest standards of safety and efficacy. Through its unwavering dedication to quality and innovation, the company aims to transform the landscape of medical technology and improve the lives of patients worldwide.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials